Phase I clinical trial assessing SKL35501
Latest Information Update: 05 Sep 2024
At a glance
- Drugs SKL 35501 (Primary)
- Indications Solid tumours
- Focus Diagnostic use
- 05 Sep 2024 New trial record
- 30 Aug 2024 According to SK biopharmaceuticals media release, SKL35501 to enter Phase 1 clinical trials after the end of 2025